Transforming Cancer Treatment Through Targeted Alpha Therapy
We aim to develope next-generation radiopharmaceutical therapies (RPTs) that harness the unique power of lead-212 (Pb-212). Our expertise spans isotope generation, chelation chemistry, and targeted delivery platforms, enabling us to build a pipeline of best-in-class therapies designed to precisely deliver alpha radiation to cancer cells.
Pb-212: A Powerful Alpha-Emitter for Targeted Therapy
Pb-212 offers an optimal blend of favorable half-life, potent alpha emissions, and theranostic compatibility—making it a leading candidate for targeted alpha therapy (TAT). Ligantis owns the prior-art patent for developing a set of gamechanging Pb-212 TATs.
A Growing Pipeline of First-in-Class Pb-212 Therapeutics
With our development program we target solid tumors with high unmet medical need. Leveraging modular targeting platforms, we are advancing multiple candidates into preclinical followed by clinical development.
Pioneering the Next Wave of Cancer Care
Radiopharmaceutical therapy represents one of the most promising new modalities in oncology. By delivering radiation directly to tumors, Pb-212 RPTs have the potential to dramatically improve precision, potency, and patient outcomes.
We are committed to accelerating this field and bringing life-changing therapies to patients around the world.